Visão geral da empresa
Innate Pharma S.A. operates within the healthcare sector, specifically as a biotechnology firm focused on developing immunotherapies for cancer patients in France and international markets. The company's core product pipeline includes Lacutamab, identified by the ticker symbol IPHA, which is an anti-KIR3DL2 antibody currently undergoing Phase II clinical trials for the treatment of cutaneous T-cell and peripheral diseases. As of the latest reporting period, the company maintains a market capitalization of $136.00M and employs a workforce of 163 individuals to advance its therapeutic portfolio. These valuation and operational metrics indicate that Innate Pharma is a mid-cap biotechnology entity with a relatively small revenue base of $9.01M, a scale typical for firms in the early-to-mid stages of drug development that prioritize research and clinical trial expenditures over immediate profit generation. The disparity between its market capitalization and annual revenue underscores the high-risk, high-potential nature of the biotechnology industry, where significant equity value is often assigned to pipeline assets rather than established sales streams.
Saúde financeira
The financial statements for Innate Pharma S.A. reveal a revenue of $9.01M over the trailing twelve months, accompanied by a net income loss of $-49,177,000 and an EBITDA of $-52,625,000. The substantial gap between the modest revenue of $9.01M and the significant net income deficit of $-49,177,000 highlights an aggressive cost structure driven primarily by heavy research and development spending necessary to progress clinical trials. The company reported free cash flow of $-34,073,624, which indicates a continued burn rate that consumes liquid assets without generating operational cash surplus. When analyzing profitability margins, the gross margin stands at 0.0%, the operating margin is severely negative at -689.6%, and the profit margin is also recorded at 0.0%, reflecting the pre-revenue or low-revenue stage of its product lifecycle where fixed costs vastly outweigh sales. The balance sheet shows a cash position of $34.31M against total debt of $22.57M, while the debt-to-equity ratio is listed as N/A due to the negative equity position inherent in net losses. Despite the negative equity, the current ratio of 1.27 suggests that the company possesses adequate short-term liquidity to cover its current liabilities with its existing cash and near-term receivables. Return on Equity is listed as N/A given the lack of positive retained earnings, while the return on assets stands at -38.8%, indicating that the management's current operations are reducing the overall value of the asset base rather than generating returns.
Avaliação de valorização
Valuation multiples for Innate Pharma S.A. reflect the speculative nature of its asset-light, pipeline-dependent business model. The trailing twelve-month P/E ratio is listed as N/A due to the lack of earnings, whereas the forward P/E is calculated at -2.31, a metric that implies the market is pricing in future earnings expectations that are currently negative or unproven. The price-to-book ratio is reported at -5.33, a negative figure that signifies the company's market value is below its book value, often seen in biotech firms where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 15.10 and an EV/EBITDA of -2.36 provide insight into how the market values the company relative to its top-line growth potential and enterprise value, suggesting a premium assigned to the potential of its clinical pipeline. Price metrics show a 52-week high of $2.63 and a 52-week low of $1.17, indicating a trading range of approximately 127% over the past year. The stock's beta of 0.74 suggests that its price volatility is lower than the broader market, potentially offering a degree of relative stability compared to high-beta biotechnology peers during periods of market fluctuation.
Growth & Income
In terms of growth dynamics, Innate Pharma S.A. experienced a revenue decline of -46.7% year-over-year, while the earnings growth rate is listed as N/A due to the company's continued profitability challenges. The negative revenue growth trajectory indicates a contraction in top-line sales or a shift in commercial focus, which is critical for investors to monitor as the company transitions between clinical phases. Regarding income generation, the company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividend payments aligns with the company's lifecycle stage, where all available cash and future earnings are retained to fund ongoing research, development, and clinical trial operations rather than being distributed to shareholders. Consequently, the overall growth and income profile of Innate Pharma S.A. is characterized by significant cash burn, negative revenue momentum, and a complete reliance on capital markets or cash reserves to sustain operations until potential regulatory approval of its immunotherapy products.